Study of YTS109 cells for autoimmune hemolytic anemia
Part of Blood & lymphatic, Immune system & allergy clinical trials.
This trial tests a new cell treatment called YTS109 for people with autoimmune hemolytic anemia (AIHA) that has not improved after several standard treatments. The goal is to see if this treatment can help control the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 12 years or older.
- You have been diagnosed with autoimmune hemolytic anemia (AIHA) or Evans syndrome.
- You have tried at least 3 previous treatments, including steroids or rituximab, and they didn't work or you couldn't tolerate them.
- Your hemoglobin level is below 100 g/L.
- Your liver and kidney function are within acceptable levels.
- You are able to care for yourself (ECOG score 0-2) and agree to use contraception if applicable.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an experimental cell therapy called YTS109 for people with autoimmune hemolytic anemia (AIHA) or Evans syndrome that has not improved with standard treatments. The goal is to see if this therapy can help control the anemia and reduce the need for ongoing treatments.
This study tests a new cell therapy called YTS109 for people with autoimmune hemolytic anemia that hasn't improved after other treatments. The goal is to see if this therapy can help control the disease and be safe.
This trial tests a new type of cell therapy (called CAR-T) for people with autoimmune hemolytic anemia or Evans syndrome that has not improved with standard treatments. The goal is to see if this therapy can control the condition and reduce the need for ongoing immune-suppressing drugs.
This trial tests a new medicine for people with autoimmune hemolytic anemia (AIHA) that has not improved with standard treatments. The goal is to see if the drug can help control the disease and improve red blood cell counts.
This trial tests a new type of immunotherapy called CAR T-cell therapy that targets two markers on your immune cells (CD19 and BCMA). It is for people with autoimmune hemolytic anemia (AIHA) who have already tried at least 3 standard treatments without success.
This early-stage trial tests a new type of immune cell therapy (UCAR T cells) for autoimmune diseases that have not responded to usual treatments. The therapy targets specific markers on immune cells to potentially calm the overactive immune response causing your illness.
Hear when a new Autoimmune Hemolytic Anemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.